7-Hematology/Biology Department, CHU Hotel-Dieu, Nantes, France. Two patients died during treatment due to progression of the disease. The median overall survival (OS) was 4 months (range: 0.5-43), with a 1-year OS estimated as 13+7% (Figure 2) .
Median leukemia-free survival for patients achieving CR/CRi was 3.8 months (range: 1-8).
One of the non-responder patients had an unexpected CR after receiving rituximab/6-mercaptopurine/methotrexate therapy, 9 and is currently alive at 3 years from allo-SCT. At time of analysis, all patients have died of progression, except two non-responder cases.
Salvage regimen was generally tolerated well, since the large majority of grade 3/4 toxicities were expected pancytopenia. One grade-3 allergic toxicity was related to the first epratuzumab infusion, but the patient received the three other infusions without events. One grade-3 renal toxicity and one grade-4 hypertriglyceridemia of unclear etiology also were documented.
This original study reports the results of a chemoimmunotherapy with epratuzumab, an anti-CD22 humanized antibody, in the setting of older patients with B-ALL. The results, although modest, are encouraging because the patients studied here represented a very high-risk refractory/relapsed older population. Also, these results suggest that older patients may be retreated even after relapse or with refractory disease. This is of particular interest in case of donor availability. Indeed, allo-SCT remains the best consolidation for patients achieving CR2, 1 while reduced-intensity conditioning regimens now allow to perform this cellular therapy up to 70-75 years of age. 9 Unfortunately, none of the responders here could be consolidated by an allo-SCT, not because of their age (4 out of 5 were under 70 years old), but because they relapsed shortly after the second chemoimmunotherapy cycle. Thus, proceeding straight to transplant as soon as achieving CR2 might be a better approach to achieve long-term remission in these patients.
Considering epratuzumab, it remains questionable wether this antibody improves the results of the chemotherapy. To our knowledge, there is no series reporting the results of a combination of vincristine/corticosteroids in an older relapsed/refractory B-ALL population, although this remains probably one of the most routinely mild re-induction chemotherapies used in this setting. In first-line therapy, the vincristine/corticosteroid combination provides an up to 53% CR rate that is not inferior to a vincristine/corticosteroid/anthracycline-based regimen. 11 Also, the recent use of liposomal vincristine for relapsed/refractory ALL showed results comparable to those we now describe (35% overall response and 20% CR/CRi). 12 Thus, it is difficult to conclude whether epratuzumab will increase the therapeutic results of a non-intensive salvage chemotherapy in the particular setting studied here. Nevertheless, more interestingly, epratuzumab may provide an important addition in terms of induction of MRD.
Indeed, 2 of our 5 responders were documented with negative MRD, which is currently considered, at least in younger patients, as a marker of long-term disease-free survival. 13 In a recent study (submitted for publication) by Raetz et al, 14 the addition of epratuzumab did also not translate in a higher CR rate in pediatric ALL patients in relapse, but of the children in CR, those treated with epratuzumab were significantly more likely to become MRD negative as compared to those treated without epratuzumab. Moreover, in the series of Advani et al, which tested a combination of clofarabine/cytarabine/epratuzumab in younger patients with refractory/relapsed B-ALL, one patient achieved negative MRD and survived 11 months, much longer than all of the other patients for which the median OS was 5 months. All patients were monitored at the CHU of Nantes for CD22 expression before treatment and then for phenotypic MRD (Dr Nelly Robillard). Leukemic blasts were evaluated using a 8 colors panel including antibodies to CD45, CD19, CD10, CD34, CD38, CD58, CD20 and CD22. MRD was assessed, concomitantly to responses, between 4 and 6 weeks after beginning the salvage regimen using flow cytometry (FACS CANTO II, BD, Biosciences, San Jose, CA) performed on bone marrow samples. Two different anti-CD22 antibodies were used. The RFB4 antibody (PE conjugated, Invitrogen, Camarillo, CA) and epratuzumab binds competitively to with RFB4, meaning that in the presence of epratuzumab, RFB4 binding is blocked. By contrast, the SHCL-1 antibody (PE or PerCp-Cy5.5 conjugated, BD Biosciences, San Jose, CA) binds to a non-crossblocking epitope and can be used to assess the modulation of the CD22 antigen on the blasts surface. None of the non-responders nor the three patients with detectable MRD showed CD22 expression as assessed with RFB4 antibody. By contrast, all showed full CD22 expression with the SHCL-1 antibody. This demonstrates a persistent targeting of epratuzumab on blasts without loss of the CD22/epratuzumab complex from the cell surface.
Case 1: An example of positive MRD. Leukemic blasts were both CD22-RFB4 and CD22-SHCL-1 positive before treatment. After treatment, the percentage of blasts is estimated at 0.05%. They are CD22-RFB4 negative and CD22-SHCL-1 positive, suggesting that epratuzumab is bound to these leukemic cells, and that the CD22-epratuzumab complex is not internalized and remains on the cell surface. 
